A retrospective, qualitative cohort study concludes that patients with sickle cell disease (SCD) may have been negatively impacted by the 2016 CDC guidance. The 2016 CDC Guideline for Opioid ...
While research has long established disparities in health outcomes among individuals living with sickle cell disease (SCD), few studies have quantified these gaps. A new study published in Blood ...
SCD is the most common inherited red blood cell disorder in the United States, affecting an estimated 100,000 people. According to the Centers for Disease Control and Prevention (CDC), SCD affects one ...
Sickle cell anemia (HbSS) is the homozygous dominant variant and the most common and severe form of the disease. Whereas patients who only inherited one gene encoding for abnormal HbS and a different ...
Sickle cell disease (SCD) is not automatically a disability by law. However, people who experience debilitating symptoms may qualify for disability benefits, and several laws protect them from ...
Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results